Furthermore, these breast TNBC GEM models (MMTV‐PyVT, MMTV‐neu) express significantly low PD‐L1 on tumor cells (Nolan et al, 2017) and do not respond effectively to PD‐1/PD‐L1 and anti‐CTLA4 immune checkpoint therapies unless given in combination of adjuvants such as cisplatin (Nolan et al, 2017). This evidence concerns the gene CTLA4 and neoplasm.